HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives

被引：15

作者：

Belema, Makonen ^{[1
]}

Nguyen, Van N. ^{[1
]}

St. Laurent, Denis R. ^{[1
]}

Lopez, Omar D. ^{[1
]}

Qiu, Yuping ^{[1
]}

Good, Andrew C. ^{[3
]}

Nower, Peter T. ^{[2
]}

Valera, Lourdes ^{[2
]}

O'Boyle, Donald R., II ^{[2
]}

Sun, Jin-Hua ^{[2
]}

Liu, Mengping ^{[2
]}

Fridell, Robert A. ^{[2
]}

Lemm, Julie A. ^{[2
]}

Gao, Min ^{[2
]}

Knipe, Jay O. ^{[4
]}

Meanwell, Nicholas A. ^{[1
]}

Snyder, Lawrence B. ^{[1
]}

机构：

[1] Bristol Myers Squibb Res & Dev, Dept Med Chem, Wallingford, CT 06492 USA

[2] Bristol Myers Squibb Res & Dev, Dept Virol, Wallingford, CT 06492 USA

[3] Bristol Myers Squibb Res & Dev, Dept Comp Aided Drug Design, Wallingford, CT 06492 USA

[4] Bristol Myers Squibb Res & Dev, Dept Metab & Pharmacokinet, Wallingford, CT 06492 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 15期

关键词：

Daclatasvir; HCV; NS5A; Mandelamide X-ray; Pan-genotype HCV replicon inhibition; Phenylglycine; HEPATITIS-C VIRUS; PLUS RIBAVIRIN; THERAPY; DACLATASVIR; ASUNAPREVIR; INFECTION;

D O I：

10.1016/j.bmcl.2013.05.040

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The isoquinolinamide series of HCV NS5A inhibitors exemplified by compounds 2b and 2c provided the first dual genotype-1a/1b (GT-1a/1b) inhibitor class that demonstrated a significant improvement in potency toward GT-1a replicons compared to that of the initial program lead, stilbene 2a. Structure-activity relationship (SAR) studies that uncovered an alternate phenylglycine-based cap series that exhibit further improvements in virology profile, along with some insights into the pharmacophoric elements associated with the GT-1a potency, are described. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：4428 / 4435

页数：8

共 50 条

[21] Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier
Abdallah, Mennatallah
Hamed, Mostafa M.
Frakolaki, Efseveia
Katsamakas, Sotirios
Vassilaki, Niki
Bartenschlager, Ralf
Zoidis, Grigoris
Hirsch, Anna K. H.
Abdel-Halim, Mohammad H.
Abadi, Ashraf
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 229
[22] Discovery of fluorobenzimidazole HCV NS5A inhibitors
Randolph, John
Flentge, Charles
Patel, Sachin
Nelson, Lissa
Mondal, Rubina
Mistry, Neeta
Reisch, Tom
Dekhtyar, Tatyana
Krishnan, Preethi
Pilot-Matias, Tami
Beno, David
Wagner, Rolf
Kati, Warren
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
[23] Discovery of fluorobenzimidazole HCV NS5A inhibitors
Randolph, John T.
Flentge, Charles A.
Donner, Pamela
Rockway, Todd W.
Patel, Sachin V.
Nelson, Lissa
Hutchinson, Douglas K.
Mondal, Rubina
Mistry, Neeta
Reisch, Thomas
Dekhtyar, Tatyana
Krishnan, Preethi
Pilot-Matias, Tami
Stolarik, Deanne F.
Beno, David W. A.
Wagner, Rolf
Maring, Clarence
Kati, Warren M.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (22) : 5462 - 5467
[24] The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymerase
Eastman, Kyle J.
Parcella, Kyle
Yeung, Kap-Sun
Grant-Young, Katharine A.
Zhu, Juliang
Wang, Tao
Zhang, Zhongxing
Yin, Zhiwei
Beno, Brett R.
Sheriff, Steven
Kish, Kevin
Tredup, Jeffrey
Jardel, Adam G.
Halan, Vivek
Ghosh, Kaushik
Parker, Dawn
Mosure, Kathy
Fang, Hua
Wang, Ying-Kai
Lemm, Julie
Zhuo, Xiaoliang
Hanumegowda, Umesh
Rigat, Karen
Donoso, Maria
Tuttle, Maria
Zvyaga, Tatyana
Haarhoff, Zuzana
Meanwell, Nicholas A.
Soars, Matthew G.
Roberts, Susan B.
Kadow, John F.
MEDCHEMCOMM, 2017, 8 (04) : 796 - 806
[25] Antiviral activity and resistance of HCV NS5A replication complex inhibitors
Gao, Min
CURRENT OPINION IN VIROLOGY, 2013, 3 (05) : 514 - 520
[26] Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors
Dwyer, Michael P.
Keertikar, Kerry M.
Chen, Lei
Tong, Ling
Selyutin, Oleg
Nair, Anilkumar G.
Yu, Wensheng
Zhou, Guowei
Lavey, Brian J.
Yang, De-Yi
Wong, Michael
Kim, Seong Heon
Coburn, Craig A.
Rosenblum, Stuart B.
Zeng, Qingbei
Jiang, Yueheng
Shankar, Bandarpalle B.
Rizvi, Razia
Nomeir, Amin A.
Liu, Rong
Agrawal, Sony
Xia, Ellen
Kong, Rong
Zhai, Ying
Ingravallo, Paul
Asante-Appiah, Ernest
Kozlowski, Joseph A.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (16) : 4106 - 4111
[27] Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir
Belema, Makonen
Nguyen, Van N.
Bachand, Carol
Deon, Dan H.
Goodrich, Jason T.
James, Clint A.
Lavoie, Rico
Lopez, Omar D.
Martel, Alain
Romine, Jeffrey L.
Ruediger, Edward H.
Snyder, Lawrence B.
St Laurent, Denis R.
Yang, Fukang
Zhu, Juliang
Wong, Henry S.
Langley, David R.
Adams, Stephen P.
Cantor, Glenn H.
Chimalakonda, Anjaneya
Fura, Aberra
Johnson, Benjamin M.
Knipe, Jay O.
Parker, Dawn D.
Santone, Kenneth S.
Fridell, Robert A.
Lemm, Julie A.
O'Boyle, Donald R., II
Colonno, Richard J.
Gao, Min
Meanwell, Nicholas A.
Hamann, Lawrence G.
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (05) : 2013 - 2032
[28] Synthesis and evaluation of novel potent HCV NS5A inhibitors
Zhang, Hongwang
Zhou, Longhu
Amblard, Franck
Shi, Junxing
Bobeck, Drew R.
Tao, Sijia
McBrayer, Tamara R.
Tharnish, Phillip M.
Whitaker, Tony
Coats, Steven J.
Schinazi, Raymond F.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (14) : 4864 - 4868
[29] Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors
Belema, Makonen
Lopez, Omar D.
Bender, John A.
Romine, Jeffrey L.
St Laurent, Denis R.
Langley, David R.
Lemm, Julie A.
O'Boyle, Donald R., II
Sun, Jin-Hua
Wang, Chunfu
Fridell, Robert A.
Meanwell, Nicholas A.
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (05) : 1643 - 1672
[30] DOSE-RANGING TRIAL OF PPI-461, A POTENT NEW PAN-GENOTYPIC HCV NS5A INHIBITOR, IN PATIENTS WITH HCV GENOTYPE-1 INFECTION
Lalezari, Jay
Agarwal, Kosh
Dusheiko, Geoffrey M.
Brown, Ashley S.
Weis, Nina
Christensen, Peer B.
Laursen, Alex L.
Asmuth, David M.
Vig, Pamela
Ruby, Eric
Huang, Ningwu
Huang, Qi
Colonno, Richard
Harding, Giles D.
Brown, Nathaniel A.
HEPATOLOGY, 2011, 54 : 400A - 400A

← 1 2 3 4 5 →